分析测试百科网 认证会员，请放心拨打！
诚信认证:
工商注册信息已核实！
扫一扫即可访问手机版展台
安捷伦中国在2019年卓越职场Great Place to Work®评选活动中金榜题名，荣膺大中华区最佳职场™，且位列前五，以及大中华区女性最佳职场™。点击了解更多
使用 SEC 和质谱分析抗体药物偶联物
| 领域： | 其他 | ||
| 样品： | 抗体药物偶联物 | 项目： | 分析抗体药物偶联物 |
| 参考： | - | ||
| 方案文件名 | 下载 |
|---|---|
使用 SEC 和质谱分析抗体药物偶联物 |
下载此篇方案 |
Recombinant monoclonal antibodies (mAbs) have emerged as important therapeutic agents for the treatment of different diseases. This technology has been extended by the development of antibody drug conjugates (ADCs). ADCs are mAbs to which cytotoxic payloads are covalently attached, enabling the delivery of potent drugs to a specific target. This Application Note describes the analysis of an mAb (trastuzumab) and an ADC (trastuzumab emtansine) by size exclusion chromatography with online mass spectrometry (SEC-MS) using the Agilent 1290 Infinity II LC system with an Agilent 6530 Accurate Mass Q-TOF LC/MS system. We demonstrate that SEC is a straightforward way to introduce mAbs and ADCs into the LC/MS system, requiring little method optimization. From the MS data collected for the ADC, it was possible to calculate a drug-to-antibody ratio (DAR) of 3:2.
扫描下方二维码，关注“安捷伦视界”微信公众号，获取更多解决方案资讯。
